FI924982A7 - Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta - Google Patents

Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta Download PDF

Info

Publication number
FI924982A7
FI924982A7 FI924982A FI924982A FI924982A7 FI 924982 A7 FI924982 A7 FI 924982A7 FI 924982 A FI924982 A FI 924982A FI 924982 A FI924982 A FI 924982A FI 924982 A7 FI924982 A7 FI 924982A7
Authority
FI
Finland
Prior art keywords
freeze
monoclonal antibody
preparation containing
dried preparation
containing monoclonal
Prior art date
Application number
FI924982A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI924982L (fi
FI924982A0 (fi
Inventor
Yasuyuki Kuroiwa
Tamotsu Fukuda
Yukio Shimazaki
Shiro Takagi
Original Assignee
Mitsui Toatsu Chemicals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI924982(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Toatsu Chemicals Incorporated filed Critical Mitsui Toatsu Chemicals Incorporated
Publication of FI924982L publication Critical patent/FI924982L/fi
Publication of FI924982A0 publication Critical patent/FI924982A0/fi
Publication of FI924982A7 publication Critical patent/FI924982A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FI924982A 1991-03-08 1992-02-28 Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta FI924982A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08
PCT/JP1992/000226 WO1992015331A1 (en) 1991-03-08 1992-02-28 Lyophilized monoclonal antibody preparation

Publications (3)

Publication Number Publication Date
FI924982L FI924982L (fi) 1992-11-04
FI924982A0 FI924982A0 (fi) 1992-11-04
FI924982A7 true FI924982A7 (fi) 1992-11-04

Family

ID=12663510

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924982A FI924982A7 (fi) 1991-03-08 1992-02-28 Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta

Country Status (10)

Country Link
US (1) US5908826A (OSRAM)
EP (2) EP0531539B1 (OSRAM)
JP (1) JPH0565233A (OSRAM)
AU (1) AU645187B2 (OSRAM)
CA (1) CA2082169A1 (OSRAM)
DE (2) DE69225757T2 (OSRAM)
DK (2) DK0531539T3 (OSRAM)
FI (1) FI924982A7 (OSRAM)
NO (1) NO924279L (OSRAM)
WO (1) WO1992015331A1 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AU2002324556A1 (en) * 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
EP2204190A1 (en) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
US8496930B2 (en) * 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
JP4671864B2 (ja) * 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
EP1712240B1 (en) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
JP5623743B2 (ja) * 2006-10-20 2014-11-12 アムジエン・インコーポレーテツド 安定なポリペプチド製剤
MX2009010179A (es) * 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
TW201618774A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
MA42613A (fr) 2015-08-13 2018-06-20 Amgen Inc Filtration en profondeur chargée de protéines de liaison à un antigène
WO2017077507A1 (en) 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
US20240417445A1 (en) * 2023-06-13 2024-12-19 Grifols Worldwide Operations Limited Method for producing a lyophilized composition comprising polyclonal igm and composition obtained

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
JP2725041B2 (ja) * 1986-12-15 1998-03-09 三井東圧化学株式会社 ヒトモノクローナル抗体とそれを有効成分とする感染症の予防、治療剤
ES2045027T3 (es) * 1987-08-10 1994-01-16 Miles Inc Igm purificadas.
WO1989011298A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Formulation for antibody reagents
CA2049342A1 (en) * 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Also Published As

Publication number Publication date
EP0531539B1 (en) 1998-06-03
NO924279D0 (no) 1992-11-06
DE69232617T2 (de) 2002-10-31
FI924982L (fi) 1992-11-04
EP0531539A1 (en) 1993-03-17
DE69232617D1 (de) 2002-06-27
NO924279L (no) 1992-11-06
EP0841067A1 (en) 1998-05-13
EP0841067B1 (en) 2002-05-22
DE69225757D1 (de) 1998-07-09
CA2082169A1 (en) 1992-09-09
DE69225757T2 (de) 1998-12-03
FI924982A0 (fi) 1992-11-04
JPH0565233A (ja) 1993-03-19
AU645187B2 (en) 1994-01-06
DK0531539T3 (da) 1998-10-12
AU1337592A (en) 1992-10-06
US5908826A (en) 1999-06-01
EP0531539A4 (OSRAM) 1995-04-05
DK0841067T3 (da) 2002-07-15
WO1992015331A1 (en) 1992-09-17

Similar Documents

Publication Publication Date Title
DK0841067T3 (da) Frysetørret præparation indeholdende et monoklonalt antistof
DK666389A (da) Monoklonalt antistof
FI930580L (fi) Tri- och tetravalensiska monopecifika antigen bindande proteiner
NZ236000A (en) Oligomeric monoclonal igg antibody composition
FI925631L (fi) Monoklonala antikroppar
IL99363A0 (en) Pharmaceutical compositions comprising homoconjugated monoclonal antibodies
DE68914244D1 (de) Monoklonaler Antikörper.
DK63187A (da) Krydsbeskyttende monoklonale antistofpraeparater
EP0580859A4 (en) Anti-eda monoclonal antibody
NO920523D0 (no) Ige-reseptor-antistoff
FI895287A7 (fi) Fukosyylikeramidin vastainen monoklonaalinen vasta-aine
EP0506523A3 (en) Monoclonal antibodies
DK717888D0 (da) Monoklonale antistoffer
DK474189A (da) Monoklonalt antistof
DK370089A (da) Anti-urokinase monoklonale antistoffer
DE69023717D1 (de) Monoklonaler Antikörper.
DK413389D0 (da) Monoklonale antistoffer
NO924803D0 (no) Tumor-relatert monoklonalt antistoff 88bv59
FI935038L (fi) Tumoer associerad monoklonal antikropp 81av78
DK220688D0 (da) Monoklonalt antistof
SE9002605D0 (sv) Antikroppssubstans
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
ITMI910660A0 (it) Anticorpi monoclonali come antidoti
SE9002479D0 (sv) Antibody conjugates
DE69324928D1 (de) Monoklonaler antikörper

Legal Events

Date Code Title Description
FD Application lapsed